One of the big winners in the pharmaceuticals space this week was Horizon Pharma (NASDAQ:HZNP), up 17% in a single day on news that it was moving to Ireland to avoid higher U.S. tax rates. The company accomplished the move by buying Ireland's own Vidara Therapeutics for $660 million, and renaming the new combined company Horizon Pharma PLC. The move is expected to directly affect the bottom line, but the top line wasn't forgotten. Horizon revised guidance for its annual sales upward, boosted by sales of Vidara's drug actimmune. 

In this segment from Friday's Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass take a look at the move from Horizon, and why they expect this emerging trend in the pharma space to continue.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.